Compare Lyumjev and Semglee to Other Insulins

August 2020

Lyumjev (insulin lispro) and Semglee (insulin glargine) will be two new BRANDS of insulin that may pop up on home med lists.

Lyumjev starts working about 10 minutes faster than other lispro products (Admelog, Humalog)...due to additives that speed absorption. It's an "ultrafast-acting" insulin...similar to Fiasp (insulin aspart).

But this doesn't matter much. Lyumjev and Fiasp's A1C reduction and hypoglycemia risk seem similar to other rapid-acting insulins.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Infectious Diseases Consider Steroids for Some Hospitalized COVID-19 Patients
Venous Thromboembolism Weigh VTE Prevention Strategies in COVID-19
Influenza Optimize Flu Vaccinations for 2020-21
Antimicrobial Stewardship Focus on Antimicrobial Stewardship During Care Transitions
Emergency Medicine Advise on Safe Med Use for Rapid Sequence Intubation
Pediatrics Use the "KIDs List" to Identify Risky Meds in Children
Insulin Compare Lyumjev and Semglee to Other Insulins
Wound Care Identify Who Needs Tetanus Vaccine and Immune Globulin
Gastroenterology Address Med Concerns for Patients With Dysphagia

Compare Lyumjev and Semglee to Other Insulins

Get unlimited access through an Enterprise license

Table of Contents